These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 21140159

  • 21. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.
    Villaseca P, Hormaza P, Cárdenas I, Oestreicher E, Arteaga E.
    Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):155-65. PubMed ID: 15697105
    [Abstract] [Full Text] [Related]

  • 22. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 23. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC.
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [Abstract] [Full Text] [Related]

  • 24. Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
    Vexiau P, Vexiau-Robert D, Martineau I, Hardy N, Villette JM, Fiet J, Cathelineau G.
    Horm Metab Res; 1990 Apr; 22(4):241-5. PubMed ID: 2141001
    [Abstract] [Full Text] [Related]

  • 25. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Apr; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 26. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A.
    Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
    [Abstract] [Full Text] [Related]

  • 27. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
    Zueff LF, Martins WP, Vieira CS, Ferriani RA.
    Ultrasound Obstet Gynecol; 2012 Mar; 39(3):341-7. PubMed ID: 21898634
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
    Kasule J, Mbizvo M, Makuyana D, Masona D.
    Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
    [Abstract] [Full Text] [Related]

  • 29. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW, Fisher AC, Hall N, Shangold GA.
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [Abstract] [Full Text] [Related]

  • 30. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L, Dordoni D, Gastaldi C, Gastaldi A.
    Acta Eur Fertil; 1986 Mar; 17(1):19-25. PubMed ID: 2941960
    [Abstract] [Full Text] [Related]

  • 31. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [Abstract] [Full Text] [Related]

  • 32. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF.
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [Abstract] [Full Text] [Related]

  • 33. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
    Pepene CE.
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):119-25. PubMed ID: 21740456
    [Abstract] [Full Text] [Related]

  • 34. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F, Carlioglu A, Kaygusuz I, Gumus II, Uz B, Akdeniz D.
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [Abstract] [Full Text] [Related]

  • 35. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
    Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F.
    Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
    [Abstract] [Full Text] [Related]

  • 36. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb 01; 118(2):209-13. PubMed ID: 15653205
    [Abstract] [Full Text] [Related]

  • 37. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.
    Contraception; 2007 Jun 01; 75(6):430-7. PubMed ID: 17519148
    [Abstract] [Full Text] [Related]

  • 38. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C, McGrath BP, Teede HJ.
    Diabetes Care; 2007 Mar 01; 30(3):471-8. PubMed ID: 17327307
    [Abstract] [Full Text] [Related]

  • 39. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec 01; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.